Cambridge Innovation Capital
Cambridge Innovation Capital is a Cambridge deep-tech and life-sciences venture firm founded in 2013 to back University of Cambridge ecosystem spin-outs, typically at Series A. It launched in 2013 with GBP 50 million from Invesco Perpetual, Lansdowne Partners, the Cambridge University Endowment Fund, ARM and IP Group, grew its first vehicle to GBP 275 million, closed Fund II at GBP 225 million (USD 300 million) in April 2022, and launched a GBP 100 million Opportunity Fund in February 2025 anchored by Aviva Investors and British Patient Capital. The operating company is Cambridge Innovation Capital Limited (Companies House number 08243718) and its manager, Cambridge Innovation Capital Manager Limited, is authorised and regulated by the UK Financial Conduct Authority under firm reference number 918898.
Key facts
Recent exits
Coverage notes
4 funds tracked, 32 portfolio companies (23 active · 9 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Cambridge Innovation Capital has raised, with its portfolio companies. Hand-checked from public filings.
CIC Opportunity FundVC2025 · 1yr€100M2 active
Unrealized
2 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| BeyondMath | AI/ML | UK | 2026 |
| Trent AI | AI/ML | UK | 2026 |
CIC Fund IIIVC2025 · 1yr€293M0 active
No portfolio companies tracked yet.
CIC Fund IIVC2022 · 4yr€263M12 active · 2 realized
Unrealized
12 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Cambridge GaN Devices | Deep Tech | UK | 2022 |
| Complement Therapeutics | Biotech | UK | 2023 |
| Epitopea | Biotech | UK | 2022 |
| Forefront RF | Telecom | UK | 2024 |
| Immutrin | Biotech | UK | 2025 |
| Mosaic TX | Biotech | UK | 2023 |
| Nuclera | Biotech | United Kingdom | 2024 |
| Pretzel Therapeutics | Biotech | USA | 2022 |
| Salience Labs | Deep Tech | UK | 2022 |
| T-Therapeutics | Biotech | UK | 2023 |
| TRIMTECH Therapeutics | Biotech | UK | 2025 |
| Unlikely AI | AI/ML | UK | 2022 |
CIC Fund IVC2013 · 13yr€322M9 active · 7 realized
Unrealized
9 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Bicycle Therapeutics | Biotech | UK | 2016 |
| Carrick Therapeutics | Biotech | UK | 2016 |
| CMR Surgical | MedTech | UK | 2016 |
| Microbiotica | Biotech | UK | 2016 |
| Pragmatic Semiconductor | Deep Tech | UK | 2014 |
| Riverlane | Deep Tech | UK | 2017 |
| Secondmind | AI/ML | UK | 2017 |
| Sense Biodetection | MedTech | UK | 2019 |
| STORM Therapeutics | Biotech | UK | 2016 |
Realized
7 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Abcodia | HealthTech | UK | 2015 | 2022 | Trade Sale | – | |
| Audio Analytic | AI/ML | UK | 2017 | 2022 | Trade Sale | – | |
| Cytora | InsurTech | UK | 2017 | 2025 | Trade Sale | – | |
| Gyroscope Therapeutics | Biotech | UK | 2019 | 2021 | Trade Sale | – | |
| Inivata | HealthTech | UK | 2016 | 2021 | Trade Sale | – | |
| PredictImmune | HealthTech | UK | 2019 | 2024 | Liquidation | – | – |
| Seldon | AI/ML | UK | 2020 | 2026 | Liquidation | – | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a UK preferred venture capital investor for the University of Cambridge ecosystem with approximately £600 million of assets under management as of December 2024, headquartered in Cambridge. The firm was founded in 2013 as the strategic partner of the University of Cambridge, anchored in the Cambridge cluster spinout pipeline. CIC remains a partner-owned independent VC platform with exclusive scale-up investor status across Cambridge spinouts.
Investment thesis
CIC deploys capital through three plus active vehicles (Fund I, Fund II, Fund III early-stage £250 million 2025 plus £100 million Opportunity Fund 2025), targeting early-stage and growth venture investments in deep-tech and life sciences spinouts from the Cambridge cluster. The Opportunity Fund enables late-stage follow-ons up to £20 million per round, addressing the UK growth-financing gap that historically constrained Cambridge spinout scale-up. Sector focus spans artificial intelligence, quantum computing, semiconductors, therapeutics, medtech and diagnostics, digital health and genomics. Geographic deployment is anchored on Cambridge ecosystem with broader UK reach.
Recent activity
Recent investments include Pragmatic Semiconductor (chips, 2025), Riverlane (quantum computing, 2024-2025) and commitments to multiple Cambridge spinouts under Fund III (2025). Realised exits across the 2024-2025 period emphasised follow-on rounds over secondary realisations, with gene therapy and biotech exits forming the historical baseline. The platform continues active deployment across the Cambridge spinout pipeline and Opportunity Fund late-stage strategy. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.